Millipore Corporation has announced that it has purchased the assets associated with Epitome Biosystems' Epitag technology for an undisclosed price.
The technology acquisition will enable Millipore's bioscience division to expand its presence in the fast-growing multiplex immunoassay market by offering scientists a broader portfolio of cell signalling assays that can be used with the Luminex Xmap platform.
Additionally, the acquisition will allow for the future development of other novel profiling technologies.
The ability of scientists to leverage multiplex cell signalling assays as a research tool has historically been limited due to the lack of highly-specific antibodies for intra-cellular targets.
The Epitag technology uses a bioinformatics-driven approach to develop high-quality antibodies that are more specific and selective than other reagents on the market.
Using the Epitag technology, Millipore expects to develop a range of multiplex immunoassay kits that will enable researchers to more efficiently measure, detect and analyse proteins and cell signalling pathways.
